08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with no substantive changes to coverage criteria. The policy continues to cover this gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity requirements. No billing or documentation workflow changes are required.